Journal of Clinical Lipidology
Volume 4, Issue 3 , Page 196 , May 2010

Letter to the Editor

References 

  1. Nash DT. Cholesterol, lipoproteins, and cognitive impairment. J Clin Lipid. 2009;3:368–371
  2. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging. 1990;11L:601–607
  3. van Exel E, de Craen AJ, Gussekloo J, et al. Association between HDL and cognitive impairment. Ann Neurol. 2002;51:716–721
  4. Craft S, Asthana S, Cook DG, et al. Insulin dose-response on memory and plasma amyloid precursor protein in Alzheimers's diease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 2003;28:809–822
  5. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169–178
  6. Baura GD, Foster DM, Kaiyala K, Porte D, Kahn SE, Schwartz MW. Insulin transport from plasma into the CNS is inhibited by dexamethasone in dogs. Diabetes. 1996;45:86–90
  7. Sanders AE, Wang C, Katz M, Derby CA, Barzilai N, Ozelius L, et al. Association of a functional polymorphism in the CETP gene with memory decline and incidence of cementia. JAMA. 2010;303:150–158
  8. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813–817
  9. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62:753–757

PII: S1933-2874(10)00057-7

doi: 10.1016/j.jacl.2010.02.010

Journal of Clinical Lipidology
Volume 4, Issue 3 , Page 196 , May 2010

Article Tools